Cancer

Small charity eases struggles of breast cancer patientsRestricted Content

October 6, 2012
Dan Human
With volunteer leader Nancy Shepard at the helm, IWIN Foundation has distributed $875,000 in grants to breast cancer patients. Recipients have ranged in age from 18 to 90.
More

Sledge's exit will keep IU program mostly intact

October 1, 2012
J.K. Wall
The departure of Dr. George Sledge likely will sap the breast cancer research program at the Indiana University Melvin and Bren Simon Cancer Center of about $500,000 in annual funding. But the program Sledge built over the past three decades mostly will remain intact.
More

Lilly wins appeal upholding patent for Alimta cancer drug

August 24, 2012
Bloomberg News
Eli Lilly and Co. won a U.S. appeals court ruling that upholds the validity of a patent for the lung-cancer drug Alimta and blocks generic competition through 2017. Alimta generated $2.5 billion in sales last year.
More

Indiana Blood Center tapping new vein of revenueRestricted Content

July 28, 2012
Mason King
Group sees role in cellular therapy as growth area with profit margins higher than core business.
More

Lilly cancer treatment fails trial in stomach cancer

July 5, 2012
 IBJ Staff and Bloomberg News
Erbitux, a cancer treatment made by Indianapolis-based Eli Lilly and Co.'s Imclone unit, failed to help patients with advanced stomach tumors in a late-stage clinical trial.
More

Cancer tools help Roche with Alzheimer's drug

May 13, 2012
Bloomberg News
Treatments for central nervous system diseases have a huge potential payoff, analysts say. A hint of whether the gamble may pay off is due in the second half of this year, as Eli Lilly and Co. and Pfizer Inc. announce results for Alzheimer’s drugs that attack the same protein as Roche’s experimental drug.
More

WellPoint enrolls IBM supercomputer at IU medical schoolRestricted Content

April 21, 2012
J.K. Wall
IBM’s supercomputer Watson is already a “Jeopardy!” champion. Now, three doctors in Indianapolis are trying to teach it how to treat cancer.
More

Komen grant recipients cope with controversy they didn't createRestricted Content

April 7, 2012
Kathleen McLaughlin
Local health care providers won’t find an easy replacement for the grant money supplied by Susan G. Komen for the Cure. That money could be in jeopardy, as grass-roots Komen supporters appear to be sitting out of this year’s Race for the Cure in response to a national controversy over grants to Planned Parenthood.
More

Endocyte pulls trigger on European drug submission

March 13, 2012
J.K. Wall
Endocyte Inc. will submit its ovarian cancer drug EC145 for European market approval in the third quarter of this year after the European Commission granted it orphan drug status.
More

Endocyte stays course despite being battered by investorsRestricted Content

December 31, 2011
J.K. Wall
After spending most of 2011 as a Wall Street darling, the year ended ugly for Endocyte Inc. But CEO Ron Ellis thinks the West Lafayette-based drug developer is in better position than ever.
More

NFP of NOTE: Little Red Door Cancer AgencyRestricted Content

December 31, 2011
 IBJ Staff
Little Red Door Cancer Agency strives to make the most of life and the least of cancer.
More

Q&A

December 27, 2011
J.K. Wall

Dr. Bryan Schneider, a professor at the Indiana University School of Medicine, led a team of researchers in identifying genetic variations that dispose some breast cancer patients to neuropathy when they are receiving chemotherapy with the drug Taxol. Schneider’s research was named one of the biggest advances in cancer research this year by the American Society of Clinical Oncology. The society’s foundation also gave Schneider a three-year, $450,000 grant to further the research.

More

Q&A

December 5, 2011
J.K. Wall
Carmel resident David Wasilewski has launched WhatNext, a website that uses algorithms to make it easier for cancer patients to connect with others in similar circumstances. Wasilewski, 39, spent eight years as chief operating officer of the Spanx line of body shapers and did health care consulting before that. In addition to helping patients, he thinks WhatNext can become a way for health care organizations share their expertise with patients in need.
More

Lilly's Alimta get favorable opinion for new use in Europe

September 26, 2011
J.K. Wall
If approved for continuation maintenance, Eli Lilly and Co.'s Alimta could be used for longer stretches in lung cancer patients, generating more revenue.
More

Debate rages over whether Lilly's Byetta lifts cancer risk

September 16, 2011
Bloomberg News
A German researcher disputed the validity of a study that found Byetta and another diabetes drug increase cancer risk.
More

IU Cancer Center recruits top researcher

September 15, 2011
Scott Olson
Dr. Murray Korc, an internationally known pancreatic cancer researcher, comes to the cancer center as the first Myles Brand Professor of Cancer Research. The position is funded through a Lilly Endowment grant.
More

IU Health strikes deal with Central Indiana Cancer Centers

June 17, 2011
J.K. Wall
Central Indiana Cancer Centers sold its five facilities to IU Health and transferred its 150 employees to the Indianapolis-based hospital system. The 16 physicians in the practice will remain independent, but they have signed a service agreement with IU Health that pulls the two entities into a tight embrace.
More

Trade agency to probe Lilly's infringement claim

March 17, 2011
Bloomberg News
Eli Lilly and Co.’s patent-infringement claim over Hospira Inc.’s generic version of the cancer treatment Gemzar will be investigated by a U.S. trade agency with the power to block imports of the copycat drug.
More

Repeated price cuts take glow off Endocyte IPORestricted Content

February 12, 2011
Greg Andrews
New investors got in for $6 a share—which is less than the average price paid by prior investors, a regulatory filing reveals.
More

Head of Lilly's oncology unit resigning

January 25, 2011
John H. Johnson has been hired as CEO by East Brunswick, N.J.-based biotechnology company Savient Pharmaceuticals Inc.
More

Lilly suspends late-stage trial for melanoma drug

December 13, 2010
Bloomberg News
Eli Lilly and Co. suspended a late-stage clinical trial of a medicine for skin-cancer patients after 12 patients in the study died.
More

Group says billboard companies rejected anti-Lilly ad

November 3, 2010
Scott Olson
San Francisco-based Breast Cancer Action wanted its message, "Eli Lilly is making us sick. Tell them to stop," posted on local billboards. But numerous sign companies refused, the group said.
More

Cancer researcher battling Semafore in courtRestricted Content

May 29, 2010
Chris O'Malley
Former collaborator alleges firm breached its agreement with him and refused to pay royalty income.
More

Positron has billion-dollar hopes for medical-imaging scanner

May 29, 2010
J.K. Wall
A maker of medical imaging equipment that recently moved its headquarters to Fishers has grand plans to reach $1 billion in sales and build a multimillion-dollar cyclotron facility in five years. But history shows Positron Corp. has been far better at losing money than making it.
More

WellPoint pledges two-day hospital stays after mastectomy

May 26, 2010
J.K. Wall
In the company's latest response to withering criticism of its breast-cancer policies, WellPoint Inc. said it will pay for any breast cancer patient to stay two days in a hospital after surgery.
More
Page  1 2 >> pager
Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. RKW's comments read like a modern "Chicken Little". As a Raintree resident for many years, "Yes, I'm ready for this." Matter of fact, I welcome The Farm because it's a development that compliments our town, brings new and desirable shopping & dining closer (specialty grocer, upscale shops, micro brew pub, etc), offers upscale condos for empty nesters who want to stay in Zionsville, is being planned and constructed by local, well-reputed firms and, of course, provides desirable non property tax benefits. We all knew the Pittman's were going to develop their property sooner than later. That one of the Pittman's will continue to live on the property helps assure The Farm will be everything promised. This also sets a standard for other developers as to the quality of future developments - which should keep an ugly Walmart at bay for decades. As we've no meglomaniac mayor, I seriously doubt Zionsville would ever aspire to over-priced statues or subsidized retail rents. And we already have a very nice public theater, the Zionsville Performing Arts Center, that meets our cultural needs quite nicely.

  2. Do we add (or subtract) these from the bounty we recieve from RTWFL, Daylight Savings Time, corporate tax giveaways, and the crack job IEDC is doing?? Or is Mike going to blame these on Mitch?

  3. Who makes Tater Tots? They would be a good sponsor, because $3 Million for the alleged "Greatest Spectacle In Racing" is taters. Tiny, tiny taters. But at least they are making up something of the losses accumulated over the years in this dying sport. Buttock in seat is certainly not doing it, nor eyeball on TV, as evidenced by the lack of both.

  4. We loved lakehouse and think the Arbor Village would be a great location. It is less than 2 miles from over 1000 rooftops in the 225,000 to over 1 million range. Many people could use the great fishers trail system to bike or walk there. Just an idea Scotty -- but maybe something closer to 3 Wiseman would good. The only microbrew in area is Ram (boring)

  5. True, it's an ESPN production, but ESPN is just another name for ABC Sports, or what used to be ABC Sports since ABC Sports no longer exists as a name. ESPN=ABC Sports= ESPN. ESPN is, according to Forbes "the world's most valuable media property" worth $40 billion. Despite that, they fired 400 people this week.

ADVERTISEMENT